This Article Full Text Full Text (PDF) Other Versions of this Article: AAC.01376-06v1 51/8/2848    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Skiadas, I. Articles by Giamarellou, H. Search for Related Content PubMed PubMed Citation Articles by Skiadas, I. Articles by Giamarellou, H.

Dexamethasone as Adjuvant Therapy to Moxifloxacin Attenuates Valve Destruction in Experimental Aortic Valve Endocarditis Due to Staphylococcus aureus

Fourth Department of Internal Medicine, University of Athens School of Medicine, University General Hospital Attikon, Athens, Greece,¹ Cardiology Department, Hippocration General Hospital, Athens, Greece,² Third Department of Internal Medicine, University of Athens School of Medicine, Sotiria General Hospital for Chest Diseases, Athens, Greece,³ Experimental Research Department of ELPEN-Pharma, Athens, Greece,⁴ Department of Histology and Embryology, University of Athens School of Medicine, Athens, Greece,⁵ Second Department of Cardiology, University of Athens School of Medicine, University General Hospital Attikon, Athens, Greece⁶

Received 3 November 2006/ Returned for modification 12 March 2007/ Accepted 29 May 2007

Although the beneficial effects of dexamethasone have frequently been investigated in various serious-infection settings, insufficient data on valve histology and cardiac function for infective endocarditis are available. The efficacy of moxifloxacin for the treatment of experimental aortic valve endocarditis due to methicillin-susceptible Staphylococcus aureus and the long-term effects of dexamethasone were evaluated in the current study. Sixty-eight rabbits were randomly assigned to four groups: A, B, C, and D. Group A consisted of 18 animals and functioned as a control group. Groups B and C consisted of 11 and 23 subjects, respectively, which received moxifloxacin for 5 days in a human-like pharmacokinetic simulation. Group D consisted of 16 animals that were administered moxifloxacin plus dexamethasone (0.25 mg/kg of body weight twice a day intravenously). The group B animals were sacrificed a day after the completion of treatment, and group C and D animals were sacrificed after 12 days in order to monitor any possible relapse and allow microbiological, histopathological, and echocardiographic evaluation of the long-term effects of glucocorticoids. No differences in survival, sterilization rates, or inflammatory infiltration and calcification of valve tissue were observed among the treated groups. However, the degrees of valve damage and collagenization were significantly worse, the fibroblast content was higher, and fractional shortening of the left ventricle fluctuated significantly in group C compared to group D (all groups, P < 0.05). We concluded that dexamethasone treatment for experimental S. aureus endocarditis attenuates valve destruction and preserves overall cardiac function without impeding the efficacy of moxifloxacin.

Published ahead of print on 11 June 2007.